Vásárhelyi Sárkányfű KFT
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVOUAC, Jérôme
SUNSTAR, NCT03227419 / 2017-000947-41: Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Recruiting
4
224
Europe
Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia
Lille Catholic University
Arthritis, Rheumatoid
09/24
11/24
SEQUENS-RA, NCT05428488: Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

Recruiting
3
220
Europe, RoW
Abatacept (W12-W48), TNF Inhibitor (W12-W48), TNF Inhibitor (W0-W12)
University Hospital, Montpellier
Rheumatoid Arthritis
11/24
11/25
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, adalimumab, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/25
12/25
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
ePRAT, NCT05124782: Virtual Management of Rheumatoid Arthritis

Recruiting
N/A
100
Europe
Rheumatoid Arthritis Impact of Disease questionnaire
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
11/23
03/24
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
SIC2, NCT05424926: Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

Active, not recruiting
N/A
22
Europe
collection of clinical parameters and blood sample
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
12/23
02/25
BASCH, André
SUNSTAR, NCT03227419 / 2017-000947-41: Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Recruiting
4
224
Europe
Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia
Lille Catholic University
Arthritis, Rheumatoid
09/24
11/24
MONITORA, NCT06528431: Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the Study

Recruiting
4
180
Europe
Clinical tapering strategy, Step Wedge trial
Centre Hospitalier Universitaire de Saint Etienne, AAP MESSIDOR
Arthritis, Rheumatoid
03/25
06/26
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, adalimumab, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/25
12/25
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
METorMET², NCT04196868: Methotrexate and Metformin in Rheumatoid Arthritis Patients

Active, not recruiting
2
128
Europe
Metformin treatment, Placebo, Methotrexate treatment
University Hospital, Bordeaux, Ministry for Health and Solidarity, France
Arthritis, Rheumatoid
06/26
06/26
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
SMART²T, NCT04749160: Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T

Completed
N/A
26
Europe
Connected device
Centre Hospitalier Universitaire de Saint Etienne
Rheumatoid Arthritis
02/22
02/22

Download Options